Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

Phase 3WithdrawnNCT01003405

Kissei Pharmaceutical Co., Ltd.100 enrolled

Overview

To investigate the long-term safety, efficacy and pharmacokinetics of KUC-7483 in patients with overactive bladder.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Overactive Bladder

Interventions

KUC-7483DRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have successfully completed the Phase III double-blind study. Exclusion Criteria: * Patients with serious adverse events or clinically significant adverse events in the Phase III double-blind study.

Locations (1)

Japan

Hokkaido,Tohoku,Kanto,Chubu,Kansai,Shikoku,Kyushu, Japan

Outcomes

Primary Outcomes

The long-term safety of KUC-7483 for the treatment of overactive bladder.

Time frame: 52 weeks

Secondary Outcomes

The long-term efficacy of KUC-7483 for the treatment of overactive bladder.

Time frame: 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.